Azienda Ospedale Università di Padova
Padova, 35128, Italy
Location status: Recruiting
NCT Number: NCT06098547
LIRICA is a prospective non-randomized study aimed at exploring the outcome of liver transplantation in selected patients with unresectable iCCA after a downstaging/disease control protocol with standard of care chemotherapy, in terms of overall survival and quality of life. Additionally, the study aims to identify pre-transplant biological markers and clinical factors that can stratify patients with the best post-transplant prognosis. Finally, the study aims to investigate the role of preoperative PET-MR, especially in relation to lymph node locations, by correlating the results with histological examination after iliac lymphadenectomy.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Not applicable
Padova, 35128, Italy
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver).
Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis.
Time frame: 3 and 5 years
Survival from time of transplantation to time of death or last follow up
Time frame: 3 years
Comparison of 3-year survival between patients enrolled in the LIRICA study and survival of a population balanced for prognostic factors and disease characteristics from the database of the Veneto Oncological Institute (IOV)
Time frame: 3 and 5 years
Survival from time of transplantation to time of death or first evidence of recurrence fo disease
Time frame: 5 years
Survival from time of recurrence to time of death or last follow up
Time frame: 3 years
Comparison of 3-year Progression-Free Survival (PFS) between the per-protocol population of patients enrolled in the LIRICA study and the PFS of the population from the Veneto Oncological Institute (IOV) database
Time frame: 5 years
Correlation of overall survival and recurrence with tissue and circulating biological markers (immunohistochemistry, proteomics, circulating tumor cells, circulating tumor DNA, new molecular markers)
Time frame: 90 days
Morbidity at 90 days (according to Clavien-Dindo and Comprehensive Complication Index, CCI)
Time frame: 3 and 5 years
Risk of mortality with sole relation to death by tumor progression and
Time frame: 5 years
Percentage of patients who do not complete the procedure (drop-out) stratified by cause
Time frame: Perioperative
Asses if suspicious lymph nodes described at the preoperative PET-RM confirm to be pathological at the histological evaluation after lymphadenectomy of the hepatic hilum and exploratory laparotomy. Lymph nodes will we evaluated by number, size and location
Time frame: 5 years
Quality of life assessed using EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer QLG Core Questionnaire) 30 items questionnaire (scale 1-4 or 1-7, 1 being the lowest and 4 or 7 the highest, accordingly)
Time frame: 5 years
Quality of life assessed using FACT-Hep questionnaire (Functional Assessment of Cancer Therapy - Hepatobiliary) questionnaire about quality of life in the last 7 days (scale 0-4, 0 being the lowest and 4 the highest)
Interested in participating?
Request InfoAzienda Sanitaria Ospedaliera
Other
Acronym: LIRICA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07841574
Adenocarcinoma, Carcinoma
Guangzhou, Guangdong, China
View Trial DetailsNCT06888063
Adenocarcinoma, Carcinoma
Rotterdam, South Holland, Netherlands
View Trial DetailsNCT07522476
Adenocarcinoma, Carcinoma
Hangzhou, Zhejiang, China
View Trial DetailsNCT06375915
Adenocarcinoma, Carcinoma
Milan, Italy
View Trial Details